Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma by Pritchard-Jones, R O et al.
Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in
malignant melanoma
RO Pritchard-Jones
1,4, DBA Dunn
1,4, Y Qiu
1, AHR Varey
1, A Orlando
2, H Rigby
3, SJ Harper
1 and DO Bates*,1
1Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, University of Bristol, Bristol, UK;
2Department of Plastic
Surgery, Frenchay Hospital, Bristol, UK;
3Department of Pathology, Frenchay Hospital, Bristol, UK
Malignant melanoma is the most lethal of the skin cancers and the UK incidence is rising faster than that of any other cancer.
Angiogenesis – the growth of new vessels from preexisting vasculature – is an absolute requirement for tumour survival and
progression beyond a few hundred microns in diameter. We previously described a class of anti-angiogenic isoforms of VEGF,
VEGFxxxb, that inhibit tumour growth in animal models, and are downregulated in some cancers, but have not been investigated in
melanoma. To determine whether VEGFxxxb expression was altered in melanoma, PCR and immunohistochemistry of archived
human tumour samples were used. In normal epidermis and in a proportion of melanoma samples, VEGFxxxb staining was seen.
Some melanomas had much weaker staining. Subsequent examination revealed that expression was significantly reduced in primary
melanoma samples (both horizontal and vertical growth phases) from patients who subsequently developed tumour metastasis
compared with those who did not (analysis of variance (ANOVA) Po0.001 metastatic vs nonmetastatic), irrespective of tumour
thickness, while the surrounding epidermis showed no difference in expression. Staining for total VEGF expression showed staining in
metastatic and nonmetastatic melanomas, and normal epidermis. An absence of VEGFxxxb expression appears to predict metastatic
spread in patients with primary melanoma. These results suggest that there is a switch in splicing as part of the metastatic process,
from anti-angiogenic to pro-angiogenic VEGF isoforms. This may form part of a wider metastatic splicing phenotype.
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Predicting tumour metastasis is one of the main goals of the
examination of the primary tumour. Most patients presenting with
melanoma (85%) are without clinically detectable metastasis at
primary excision. For these patients, histological examination is
vital for staging and obtaining a relative risk of future metastasis.
Both level of invasion within the skin (Clark’s staging; Clark et al,
1969) and, more accurately, thickness of the primary lesion
(Breslow thickness; Breslow, 1970; Balch et al, 2001b) correlate to
disease progression and survival. These prognostic indicators of
thickness and invasion are the most commonly used and indeed
the basis for staging melanoma and the development of manage-
ment strategies in terms of excision margin, sentinel node biopsy,
further investigation and follow-up. The other key indicator of
prognosis is the presence of ulceration. Patients with tumour
thickness 44mm have a 10-year survival of between 54 and 32%
(Stadelmann et al, 1998; Balch et al, 2001a; Cook et al, 2002).
Prognostic indicators to detect the patients, and especially the
13% of patients with thin melanoma (o1mm), who will go on to
develop metastasis are currently being investigated, and much
work has been focused on the density of lymphatics surrounding
primary malignant melanomas (Dadras et al, 2003; Shields et al,
2004).
A number of studies have attempted to investigate angiogenic
growth factors to determine whether they can predict metastasis,
but there is poor correlation between the most potent angiogenic
factor vascular endothelial growth factor-A (VEGF-A) and meta-
static spread (Turley et al, 1998; Straume and Akslen, 2001;
Simonetti et al, 2002; Giatromanolaki et al, 2003; Potti et al, 2003,
2004; Stefanou et al, 2004; Yang et al, 2004). Expression of
VEGF-A is an attractive potential marker of prognosis owing to its
consistent upregulation in cancer (Carmeliet, 2000), including
melanoma (Bayko et al, 1998; Bayer-Garner et al, 1999), but there
are conflicting data surrounding the prognostic implication of any
observed upregulation. Vascular endothelial growth factor-A exists
in most tissues, including cancer, as multiple isoforms generated
by alternative splicing of a single gene product. These isoforms are
termed according to the amino-acid number (VEGF121, VEGF143,
VEGF165, VEGF189 and VEGF206; Ferrara, 1999). The predominant
molecular species produced by a variety of normal physiological
and pathological tissues is VEGF165.
In 2002, we described the first isoform of a novel family of splice
variants formed by the use of a distal splice acceptor site in the
terminal exon of the VEGF-A gene encoding an open reading
frame of identical length to the classical, proximally spliced
isoforms, and resulting in proteins of the same length, but with an
alternate C terminus. The mRNA encoding this isoform, termed
VEGF165b (Bates et al, 2002; Figure 1), was demonstrated in renal
cortical tissue, and almost all other normal tissues examined.
Subsequent work has identified other isoforms using this distal
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normal human tissues (Woolard et al, 2004; Perrin et al, 2005).
This alternative family of isoforms is termed the VEGFxxxb family,
in contrast with the VEGFxxx family where xxx denotes the amino-
acid number (Perrin et al, 2005). Expression of VEGF165b mRNA
was downregulated in renal cell carcinoma (Bates et al, 2002),
prostate cancer (Woolard et al, 2004) and the vitreous of patients
with diabetic retinopathy (Perrin et al, 2005), all angiogenic
conditions. Subsequently, VEGF165b protein was shown to
significantly and dose dependently inhibit VEGF165-mediated
proliferation and migration of endothelial cells, vasodilatation of
mesenteric arteries and angiogenesis in two different models of
VEGF165-driven blood vessel growth (Woolard et al, 2004).
Furthermore, it has been shown to inhibit hypoxia-driven
angiogenesis in the retina (Konopatskaya et al, 2006). This family
of isoforms has now been termed the anti-angiogenic family of
VEGF isoforms, in contrast with the pro-angiogenic VEGFxxx
isoforms.
As the amino-acid structure of the VEGFxxxb family is 95–96%
identical to VEGFxxx, all previous studies on melanoma have not
distinguished between the pro- and anti-angiogenic isoforms. It is
therefore possible that changes in VEGF expression in melanoma
are due to changes in isoform expression, and it is this that
predicts progression or metastasis. We therefore determined
whether VEGF isoform expression was altered in melanoma.
METHODS
Primary metastatic melanoma was defined as primary tumours
removed from a patient who subsequently went on to develop
metastatic disease, confirmed to be melanoma in origin. Non-
metastatic melanoma was defined as primary tumours removed
from a patient who subsequently had not developed metastatic
disease after at least 8 years. Samples were collected, and
experiments carried out under Local Ethical Committee approval
(North Bristol NHS Trust).
Reverse transcription–PCR
Eight 5mm thick sections were cut from nine archival, formalin-
fixed, paraffin-embedded primary melanoma specimens (0.88–
8.1mm thick) from Frenchay Hospital, Bristol. These were melted,
rehydrated through alcohols and subjected to RNA extraction
(Trizol extraction method) before reverse transcription to cDNA as
previously described. The complementary DNAs, VEGF165 and
VEGF165b, were then amplified using primers specific to these two
isoforms (exon 7/8a for VEGF165: exon 7: 50-GTAAGCTTGTACA
AGATCCGCAGACG-30, exon 8a: 50-TCACCGCCTCGGCTTGTCA
CAT-30; or exon 7/8b for VEGF165b exon 8b: 50-TTAAGCTTTC
AGTCTTTCCTGGTGAGACTGCA-30), or primers that detect both
isoforms – 30 UTR: 50-ATGGATCCGTATCAGTCTTTCCTGG-30).
For exon 7/8b primers, PCR cycles were 941C for 30s, 651C for 30s
and 721C for 30s. For other primer pairs, annealing was carried
out at 551C. All PCR were carried out in 1.5mM MgCl2,2 5mM each
of dCTP, dATP, dGTP and dTTP, 1mM of each primer, using Taq
polymerase (Abgene, Epsom, UK), and 1ml of cDNA in 20ml
volume in a Hybaid DNA Express PCR machine. Products were
separated by agarose gel (3% in TAE) electrophoresis and
visualised by ethidium bromide staining (0.5mgml
 1).
Surface plasmon resonance To confirm the binding affinity of
VEGF165 and VEGF165b to the VEGF165b-specific antibody, we
amine coupled the latter to a CM5 sensor chip (Biacore AB,
Uppsala, Sweden) to an immobilisation level of 630 response units
(RU). Coupling was performed using EDC/normal horse serum
(NHS) and 1 M ethanolamine (Biacore AB) as per the manufac-
turer’s instructions, with the antibody dissolved in 10mM sodium
acetate (pH 4.5). A blank reference cell was formed by the same
activation and deactivation process involved in amine coupling,
but without adding any protein to be coupled to the surface.
Samples, containing VEGF165 or VEGF165b diluted in HBS-EP
sample buffer (HEPES-buffered saline with EDTA and P20
surfactant; Biacore AB) were then run at two-fold serial dilutions
from 180nM down, in random order, with duplicate concentrations.
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Figure 1 Alternative splicing of the VEGF gene in the terminal exon results in two families of isoforms – the angiogenic VEGFxxx and the anti-angiogenic
VEGFxxxb isoforms.
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sInjection was performed at 30mlmin
 1 for 3min, followed by
6min of buffer only. Regeneration was performed by injection of
4 M MgCl2 at 20mlmin
 1 for 40s, followed by a 2-min period of
stabilisation.
Immunohistochemistry
Pan-VEGF immunohistochemistry Sections were cut from 19
melanomas (9 metastatic and 10 nonmetastatic). These melanomas
were matched for thickness and time since taken, as closely as
possible. There was no significant difference between the
thicknesses (nonmetastatic 2.871.2mm, metastatic 4.070.9mm,
P40.25, t-test). All tumour samples were archived tissues taken
5–12 years ago and stored as paraffin-embedded blocks. There
was no statistical difference between the age of patients
(mean7s.e.m. age 58.376.9 years (metastatic) vs 60.976.2 years
(nonmetastatic) Mann–Whitney t-test P¼0.7) and tumour
ulceration (mean7s.e.m. incidence of ulceration 0.570.17 (meta-
static) vs 0.3370.16 (nonmetastatic) Mann–Whitney t-test
P¼0.2). The mean7s.e.m. follow-up time (time between excision
of the tumour and the analysis of expression) was not significantly
different between the metastatic melanoma and nonmetastatic
melanoma (7.671.3 years, metastatic; 8.570.17 years, nonmeta-
static; P40.50 t-test).
A commercially available anti-VEGF antibody A-20 (rabbit anti-
human VEGF antibody, Santa Cruz, CA, USA) was used to
investigate expression of all isoforms of VEGF (including
VEGFxxxb) – termed pan-VEGF. This antibody has previously
been shown to detect both VEGFxxxb and VEGFxxx isoforms, and
both heparin-binding and nonheparin-binding isoforms (Woolard
et al, 2004; Perrin et al, 2005). Serial sections (6mm) were cut from
tissue blocks of excised melanoma from the melanoma archive at
Frenchay Hospital, Bristol. Sections were dewaxed with xylene for
15min before rehydration in graded alcohols. Antigen retrieval
was performed with microwave treatment for 3min at 800W and
10min at 120W in 0.01 M sodium citrate buffer, pH 6.0, and the
container closure adjusted to maintain the solution just below
boiling point (96721C). Sections were immersed in 3% hydrogen
peroxide for 5min to block endogenous peroxidase. Then they
were incubated with 1.5% NHS for 30min in a humid chamber at
room temperature to block nonspecific binding. After washing,
each slide was subject to incubation with a pan-VEGF (A-20)
rabbit antibody (Santa Cruz) at 5mgml
 1 NHS. Control IgG was
used at 5mgml
 1 NHS. Sections were incubated overnight. The
blocking step with NHS was repeated before the addition of the
biotinylated horse anti-rabbit secondary antibody (2mgml
 1) for
30min. Then avidin-biotinylated enzyme complex was prepared
according to the manufacturer’s instructions (Vector Laboratories,
Burlingame, CA, USA) and incubated with sections for 30min at
room temperature. This was followed by the addition of the
visualising DAB substrate for all sections and counterstaining in
haematoxylin. Sections were dehydrated in graded alcohols (70, 90
and 100% ethanol) before final clearing in xylene and mounting
with DPX and glass coverslips. Slides were dried overnight before
light microscopy examination.
VEGFxxxb immunohistochemistry
The expression of VEGFxxxb was examined by immunohisto-
chemistry using a mouse monoclonal IgG1 antibody raised to the
terminal 9 amino acids of the VEGF165b sequence. It is affinity
purified against the antigen from conditioned media of hybridoma
cells, and is commercially available from R&D systems (Minnea-
polis, MN, USA) (cat. no. MAB3045). It has previously been shown
to have specificity for the VEGF165b isoform over the VEGF165
isoforms, and does not detect VEGF165, or VEGF121, recombinant
protein (Woolard et al, 2004; Perrin et al, 2005). It does detect
proteins consistent with VEGFxxxb isoforms such as VEGF121b,
VEGF165b, VEGF145b and VEGF189b in human tissues. Surface
plasmon resonance analysis showed that the affinity of the
antibody for VEGF165b was 3.7 10
 7 M (Figure 2A), whereas it
had no detectable binding to VEGF165 (Figure 2B). Sections were
prepared as above, and antigen retrieval was performed as above,
but in 0.02 M sodium citrate buffer, pH 6.0. Sections were
immersed in 3% hydrogen peroxide for 5min to block endogenous
peroxidase. Then they were incubated with 1.5% NHS for 30min in
a humid chamber at room temperature to block nonspecific
binding. After washing, each slide was subject to 60mlo f4mgml
 1
MAB3045 anti-VEGF165b monoclonal antibody diluted in PBS/T–
1% BSA overnight at 41C. The control received a matched
concentration of normal mouse immunoglobulin diluted in
PBS/T–1% BSA. The blocking step with NHS was repeated
before the addition of the biotinylated horse anti-mouse secondary
antibody (Vector BA-2000, 25mgml
 1 in NHS; 1:66 in PBS)
for 30min. Then avidin-biotinylated enzyme complex was
prepared and incubated with sections for 30min at room
temperature. This was followed by the addition of the visualising
DAB substrate and counterstaining in haematoxylin as above.
Sections were dehydrated in graded alcohols (70, 90 and 100%
ethanol) before final clearing in xylene and mounting with DPX
and glass coverslips. Slides were independently assessed and
staining intensity scored (0 to 3þ) as has been previously
described for VEGF staining in melanoma (Potti et al, 2003, 2004).
Light microscopy examination was performed by three different
assessors, blinded to the metastatic outcome of these tumours or
identity of the primary antibody. They were asked to grade the
intensity of staining (0–3) in the horizontal growth phase (HGP),
vertical growth phase (VGP) and peritumoral areas of each section.
The metastatic and nonmetastatic tumours were matched for
thickness, patient age and ulceration, and the staining intensity
compared.
To determine the relative intensity of the VEGF isoforms
in metastatic melanoma, the staining intensity in the melanoma
(either VGP or HGP, on a scale of 0–3) was normalised to
that in the peritumoral (histologically normal) skin for each
stain. The ratio of the two scores was then calculated (pan-VEGF/
VEGFxxxb).
VEGF165b
0
R
e
s
p
.
 
D
i
f
f
.
R
e
s
p
.
 
D
i
f
f
.
10
20
30
40
50
60
70
80 A
B
0 100 200 300 400 500 600 700
100 200 300 400 500 600 700
Time
Time (s)
0
10
20
30
40
50
60
70
80
VEGF165
180 nM
90 nM
45 nM
22.5 nM
11.25 nM
11.25–180 nM
Figure 2 Biacore analysis of recombinant human VEGF165b or VEGF165
binding to the anti-VEGF165b antibody. (A) VEGF165b bound with relatively
high affinity and dissociation constants (2.9 10
4 M
 1s
 1 and 0.011s
 1,
respectively). (B) Even at 180nM, VEGF165 showed no binding to the
antibody.
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Reverse transcription–PCR of archival tissue showed that both
VEGF165b and VEGF165 were expressed in melanoma sections
(Figure 3). Expression varied, possibly owing to variable efficiency
of RNA extraction, but VEGF165b was seen in most samples and
VEGF165 in some. To confirm that these isoforms were generated
from DSS selection and proximal splice site (PSS) selection, PCR
was carried out using isoform-specific primers. Figure 3B shows
expression of VEGF165b in three melanoma samples, whereas
VEGF165 was clearly seen in only one sample (melanoma number
2). It was therefore clear that VEGF165b was expressed in sections
of human melanoma. However, these sections contained three
different types of tissue, and mRNA was extracted from all three –
normal skin, HGP melanoma and VGP melanoma. To localise the
expression of the isoforms, we performed immunohistochemistry
using a VEGFxxxb-specific antibody.
Pan-VEGF staining of normal skin revealed VEGF expression
throughout the epidermis and only weak staining in the dermis
(Figure 4A). At higher magnification (Figure 4A; right-hand
picture), staining was also seen around blood vessels. Staining
with a VEGFxxxb-specific antibody revealed that in normal skin
VEGFxxxb was expressed in the same places as the pan-VEGF stain
– namely strong expression in the epidermis, with weaker staining
in the dermis and blood vessels (Figure 4B).
Figure 5 compares expression in and around a melanoma that
did not metastasise with the one that metastasised. In nonmeta-
static melanoma (Figure 5A–C), expression of VEGFxxxb in the
peritumoral epidermis (greater than 1mm from the tumour
margin; Figure 5A) and in the HGP (supratumoral; Figure 5B)
bv
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Figure 4 Expression of VEGF in normal skin. (A) Expression of VEGF determined by staining with antibodies that detect all isoforms (pro- and anti-
angiogenic) of VEGF (pan-VEGF antibody). Staining is seen in epidermis (e) and weak diffuse expression in dermis (d) and around blood vessels (bv). Inset is
negative control. (B) Expression of VEGFxxxb in skin. Expression was seen in epidermis, with very weak staining in dermis. Blood vessels were positive for
VEGFxxxb. Scale bars are already given in the figure.
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Figure 3 Distal and proximal splice variants of VEGF are found in archival melanoma tissues. (A) Extraction of mRNA from 8- to 10-year-old archival
sections of melanoma and surrounding skin followed by RT–PCR using primers in exon 7 and the 30 UTR of the VEGF gene resulted in two products of 150
and 200bp. These were consistent with VEGF165b and VEGF165, respectively. (B) Splice site-specific primers to the proximal splice site (PSS) and the distal
splice site (DSS) confirmed expression of these isoforms in archival sections.
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(intratumoral) of nonmetastatic melanoma, VEGFxxxb appeared
to be diffusely and widely expressed, similar to normal dermis
(Figure 5C). In metastatic melanoma, however (Figure 5D–F),
although VEGFxxxb expression appeared similar to normal dermis
in the peritumoral epidermis (Figure 5D), it was not expressed in
either the HGP (Figure 5E) or the VGP (Figure 5F).
To determine whether objective scoring of the expression
intensities was different between metastatic and nonmetastatic
samples, sections were assessed by three independent observers on
an integral scale of 0–3 (3 being the highest intensity of staining),
blind to metastatic outcome. Figure 6A shows that there was a
significant downregulation of VEGFxxxb staining intensity in
metastatic compared with nonmetastatic melanoma (Po0.001,
Kruskal–Wallis) both deep within (VGP 0.4870.26 (metastasis) vs
1.770.24 (nonmetastasis), Po0.05 Dunn’s) and on the surface
(HGP 0.3770.2 (metastasis) vs 1.5770.25 (nonmetastasis),
Po0.05 Dunn’s) but not in peritumoral epidermis (2.070.27
(nonmetastasis) vs 1.670.38, P40.05 Dunn’s). This finding held
true for both thick and thin melanoma.
To compare total VEGF expression with VEGFxxxb expression,
serial sections of 16 of the 19 melanomas matched for thickness,
ulceration and patient age were stained with the pan-VEGF
antibody. In nonmetastatic melanoma, expression of VEGF in the
peritumoral epidermis (Figure 7A), HGP (Figure 7B) and VGP
(Figure 7C) appeared to be similar to that in normal epidermis
or dermis as appropriate. In metastatic melanoma, however,
there was increased intensity of staining from peritumoral
epidermis (Figure 7D) to HGP (Figure 7E) and then to VGP
(Figure 7F). This was in complete contrast to VEGFxxxb staining.
Blind scoring of these melanomas showed that pan-VEGF
expression was slightly but significantly increased in VGP
metastatic melanomas (Po0.05; ANOVA; Figure 6B) but not in
the nonmetastatic melanomas. To determine whether the ratio of
Supratumoral Intratumoral Normal skin
Nonmetastatic melanoma 
Metastatic melanoma
C B A
F E D
Figure 5 Expression of VEGFxxxb in metastatic and nonmetastatic melanoma and surrounding skin. Expression of VEGFxxxb was lower in horizontal
(supratumoral) and vertical (intratumoral) growth phase metastatic melanoma than in nonmetastatic melanoma or normal skin. (A–C) Nonmetastatic,
(D–F) metastatic melanoma. (A and D) Histologically normal skin 41mm horizontally from tumour, (B and E) horizontal growth phase (supratumoral),
(C and F) vertical growth phase (intratumoral). Scale bars 50mm.
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Figure 6 Staining of VEGFxxxb but not that of VEGF is reduced in metastatic but not in nonmetastatic melanomas. (A) Mean7s.e.m. score from three
independent observers blinded to metastatic status of staining intensity of images of melanoma samples. (B) Pan-VEGF was not altered in nonmetastatic
melanoma, but, in contrast to VEGFxxxb, appeared to increase in metastatic melanoma from normal through horizontal growth phase (HGP) to vertical
growth phase (VGP). *¼Nonmetastatic vs metastatic, VEGFxxxb, Po0.0001 one-way analysis of variance (ANOVA), **¼Po0.01 Bonferroni.
þ ¼Compared with normal skin. VEGFxxxb: metastatic, Po0.0001 one-way ANOVA, pan-VEGF: metastatic, Po0.05, ANOVA.
þ ¼Po0.05
þþþ¼Po0.001, Dunnetts.
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the scores for each tumour relative to normal skin were normalised
to the VEGFxxxb score relative to normal skin for that tumour.
Figure 8 shows that there was a significantly higher ratio of
pan-VEGF to VEGFxxxbi nm e t a s t a t i c( n¼9) than in nonmetastatic
melanomas (n¼7).
DISCUSSION
The ability to accurately determine which patients will go on to
develop metastasis is a key goal in current melanoma therapy.
Patients are currently followed up every 3 months for 3 years, even
after removal of thin tumours, as a significant proportion (15%)
of these will go on to develop metastasis. Patients with thicker
melanoma (41mm) will be followed for a further 2 years at 6
monthly intervals (Roberts et al, 2002). Recent studies have
identified lymphatic density of the primary tumour upon excision
as a potential predictor of metastasis (Dadras et al, 2003; Shields
et al, 2004). This increased lymphatic density may be brought
about by growth of new lymphatics towards tumours expressing
VEGF-C or VEGF-D (Skobe et al, 2001), by stochastic variation of
melanomas or metastatic chemotaxis towards lymphatic endo-
thelial cells (Shields et al, 2007). The identification of increased
lymphatic density has been combined with thickness and
lymphatic invasion to generate a prognostic index (Shields’ index)
that predicts the likelihood of metastasis, at least in a relatively
small number of patients (Shields et al, 2004). Other indicators,
such as lymphatic hot spots, have also been used (Dadras et al,
2003, 2005). Both these mechanisms require the staining and
counting of lymphatic surrounding tumours, and are labour
intensive, and in the case of hot spots subjective. The identification
of molecules shown to be downregulated in melanoma would make
identification of potentially metastatic tumours easier.
The antibody used here is an affinity-purified monoclonal
antibody, and has been shown using Western blotting (Woolard
et al, 2004; Perrin et al, 2005), immunohistochemistry (Woolard
et al, 2004) and ELISA (Woolard et al, 2004; Bates et al, 2006) to
detect only the VEGFxxxb isoforms of VEGF. Samples extracted
from various human tissues, when probed with this antibody,
reveal multiple bands of the same size as that detected using a
pan-VEGF antibody – although at different relative intensities. It
has so far been shown to detect VEGF121b, VEGF165b, VEGF189b,
VEGF183b and VEGF145b but none of the VEGFxxx isoforms,
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Figure 7 In metastatic melanomas, VEGF staining, but not VEGFxxxb staining is upregulated. Although VEGF staining was clearly seen in peritumoral
epidermis, and horizontal growth phase (HGP; supra) and vertical growth phase (VGP; intra), this was in contrast to VEGFxxxb staining in serial sections. In
nonmetastatic melanomas however, VEGF staining was similar to VEGFxxxb staining in all three tissue types. (A–F) Metastatic melanoma, (G–L)
nonmetastatic melanoma, (A–C and G–I) VEGF staining, (D–F and J–L) VEGFxxxb staining, (A, D, G and J) normal skin, (B, E, H and K)
HGP(supratumoral), (C, F, I and L) VGP (intratumoral). Scale bars¼50mm.
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Figure 8 Relative levels of panVEGF to VEGFxxxb staining expression are
decreased in metastatic melanoma. The normalised ratio of VEGFxxxbt o
VEGF staining was significantly reduced in metastatic compared with
nonmetastatic melanoma (*¼Po0.05, **¼Po0.01 compared with
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et al, 2005).
The downregulation of the VEGFxxxb isoforms identified here, if
confirmed in a larger study, would greatly simplify the procedure
for identifying patients at risk. Furthermore, it could be combined
with other indices, such as the Shields’ index, to further refine
metastatic prediction (Shields et al, 2004). However, the mecha-
nisms underlying downregulation of VEGFxxxb isoforms have not
been identified here. Possible explanations of this finding include
the following: (1) VEGFxxxb expression inhibits tumour metastasis
directly by interfering with tumour cell migration or tumour cell
adhesion via a currently unknown mechanism; (2) inhibition of
angiogenesis by VEGF165b expression (Woolard et al, 2004) is
responsible for preventing metastasis by limiting tumour size
independently of thickness; (3) VEGFxxxb expression inhibits the
main route of metastatic spread via the lymphatics by inhibition of
lymphangiogenesis; (4) increased vascular permeability induced
by VEGFxxx increases the likelihood of metastasis; or (5) a
combination of any or all of the above factors.
VEGFxxxb has been shown to be anti-angiogenic in physiological
models, and inhibits melanoma xenograft growth in vivo (Woolard
et al, 2004; Konopatskaya et al, 2006), but results in a very
transient increase in vascular permeability to water (Glass et al,
2006), whereas VEGF165 is angiogenic and results in a chronic and
sustained increase in water permeability (Senger et al, 1983, 1990;
Bates and Curry, 1996), leading to oedema in many tumours.
Upregulation of VEGF165 with respect to VEGF165b will therefore
result in angiogenic, leaky tumours, and it is likely that this would
provide a more facilitative environment for metastasis for a
number of reasons. These include a more hydrated tissue, which
would be easier for cell and molecules to move through (Criscuoli
et al, 2005). This would result in tumour cells having a greater
likelihood of detecting lymphatic-secreted chemokines to identify
the lymphatics (Podgrabinska et al, 2002), and being able to
secrete heparin-binding growth factors a further distance to
stimulate lymphatic growth into the tumours. Recent studies have
also shown that lymphatic cells can migrate along patterns of
interstitial fluid flows (Boardman and Swartz, 2003), and
presumably this would be enhanced in more permeable tumours.
Thus, the expression characteristics of these tumours indicate that
upregulation of pro-angiogenic, pro-permeability VEGF165 and its
sister isoforms is associated with metastasis in melanoma. The
ratio of pan-VEGF to VEGFxxxb staining shown in Figure 8 is
qualitatively similar to an angiogenic ratio that can be calculated
from quantitative assessment of VEGF isoforms by ELISA. This
ratio reflects the angiogenic balance of VEGF isoforms and can be
considered an angiogenic ratio. For quantitative studies, a value of
1 would indicate that all the VEGF is VEGFxxxb, whereas values
above 1 indicate the presence of non-VEGF isoforms, and values
greater than 2 indicate a pro-angiogenic state. For semiquantitative
assessments such as those described here, the degree of the
angiogenic switch cannot be assessed, but it is clear that the
metastatic tumours have a more angiogenic balance of isoforms
than the nonmetastatic tumours.
These findings also show that the metastatic process appears to
be associated with a splicing switch. Recently, the role of splicing
in cancer has received a good deal of attention (Venables, 2004),
but it is clear that alternative splicing events also play a role in
the metastatic process (Venables, 2006; Tsuji et al, 2006). The
regulation of VEGF splicing may therefore also be part of a
metastatic splicing phenotype that is regulated by specific splice
factors, such as SF/ASF2, described recently for the macrophage-
stimulating promoter receptor tyrosine kinase Ron (Ghigna et al,
2005), and for which we also have evidence that it is involved in the
regulation of VEGFxxx:VEGFxxxb splicing (Woolard et al, 2006).
In summary, we have shown that VEGFxxxb proteins are
downregulated in metastatic but not in nonmetastatic malignant
melanomas, but the mechanism underlying this is not known. This
could result in a greater accuracy of prognosis for metastatic
melanoma.
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